Aggreko brings scale and leverage back to the IPO queue

Aggreko gave the U.S. pipeline its first institutional-scale filing of the week, returning a global power-rental business to public markets after five years under private-equity ownership. The company applied to list on the NYSE as AGKO, with Goldman Sachs and J.P. Morgan leading a broad syndicate. Share count and price remain blank in the initial registration statement, so the filing establishes a credible new test without yet establishing valuation.

The distinction matters. No conventional IPO priced during the week ended August 30. Several merger registrations became effective or reached final-prospectus form, while four issuers moved into public review. Aggreko is the one deal with the scale, underwriting depth and financing objective to test whether buyers will fund a sponsor-backed issuer carrying substantial debt.

Aggreko's growth meets its interest bill

Aggreko generated $3.42 billion of net revenue in the year ended January 3, 2026, up 20%, and served more than 14,000 customers across more than 80 countries. The filing positions data centers, utilities and infrastructure as major demand channels for its modular power and temperature-control fleet. Europe revenue rose 46%, helped by acquisitions, while the Americas grew 18%.

The income statement supplies the counterweight. Aggreko recorded a $113 million net loss for fiscal 2025 after a $34 million profit a year earlier, with interest expense reaching $647 million. The company says foreign-exchange movements on euro-denominated debt drove much of the increase. First-half performance improved: net income was $80 million for the six months ended July 4, 2026, versus a $189 million loss in the prior-year period.

IPO proceeds and a concurrent contribution from the existing sponsor are intended primarily to repay revolving and senior term borrowings, with any remainder available for general corporate purposes. IPOGrid reads this as a balance-sheet transaction attached to a durable operating platform. Revenue growth and a heavyweight book make Aggreko financeable; the unresolved questions are how much deleveraging the offer delivers and how much ownership the sponsors retain. Those answers will matter more than the headline revenue number when terms arrive.

Electra offers biotech depth, with no terms yet

Electra Therapeutics also made a serious public filing. The South San Francisco biotech applied for Nasdaq Global Select under ETRA, with Jefferies, TD Cowen, Evercore ISI and Cantor on the cover of its S-1. The company is developing ipsoprubart for immune-mediated diseases and ELA822 for oncology, but shares and range remain blank.

Electra held $97.7 million of cash, equivalents and marketable securities at June 30. Its net loss widened to $48.9 million in the first half from $25.4 million a year earlier. The filing is unusually direct about the financing horizon: existing resources plus IPO proceeds will not carry the candidates through trials, approval and commercialization. Our interpretation is that Electra has the syndicate and clinical focus to become a real biotech demand read, but only after deal size and runway are specified.

Dual listings seek U.S. capital

Two already-public businesses advanced U.S. offerings. Finland-listed Spinnova filed for American depositary shares under the proposed Nasdaq symbol SPNV. Its F-1 and company announcement target at least $15 million of gross proceeds, with Roth Capital leading. Funds would support the Eteläportti demonstration facility, commercialization and general purposes. The company expects the transaction in September or October, subject to approvals and market conditions.

Amaero, an Australian additive-manufacturing materials company that redomiciled to Delaware in June, publicly filed after a confidential submission in July. Its S-1 proposes a Nasdaq Global Select listing while its depositary interests continue trading in Australia. Proceeds are earmarked for capital equipment, working capital and general corporate needs. With the share count and range still blank, both transactions are pipeline additions rather than immediate price-discovery events.

AM PM doubles its proposed float

AM PM Group supplied the clearest small-cap terms change. The Hong Kong events and decoration company now proposes 7.5 million shares at $4 to $5, implying $33.75 million at the midpoint. Its February filing contemplated 3.75 million shares at the same range, so the planned base deal has doubled. The latest amendment also shows that four customers represented 69.9% of year-end receivables and five vendors represented 56.8% of payables. Prime Number Capital is the underwriter. The reviewer’s concern is that a larger float increases the demand burden while concentration remains high.

Effectiveness did not equal IPO pricing

EUROEV Holdings and United Hydrogen Global received SEC effectiveness notices, but neither event was a conventional underwritten IPO. EUROEV's final merger prospectus registers 44.7 million $10 shares tied to its acquisition of Aiways Europe. United Hydrogen's effectiveness notice advances shares issued as consideration in a de-SPAC transaction. DRC Medicine likewise filed a final prospectus for its proposed combination with Ribbon Acquisition; Ribbon shares continued to trade under RIBB during the week.

These filings move transactions toward closing, but they provide little evidence about institutional IPO demand. The week's useful setup lies ahead. Aggreko must translate scale into acceptable leverage and valuation, Electra must define its biotech financing runway, and the smaller dual listings must prove that a U.S. venue can broaden their capital base.